Key Highlights

  • Each common share was cancelled and exchanged for cash at merger close.
  • The merger triggers Nasdaq delisting and suspension of trading.
  • The company's market capitalization reflects its recent performance.
  • The cash payout provides shareholders with a fair-value exit.

Catalyst Pharmaceuticals closed its merger with Angelini Pharma's subsidiary, cancelling every outstanding share and delivering a cash payment. The transaction turned the company into a wholly owned subsidiary of Angelini Pharma, ending its independent existence on the Nasdaq Capital Market. The move follows a series of governance changes.

The cash consideration was paid without interest, and the shares were removed from Nasdaq’s listing. The company notified the exchange of the consummation and asked that trading halt. Consequently, trading of the stock will be suspended.

This final step eliminates any future equity participation for former shareholders, locking in the cash value they received.

Transaction Mechanics and Governance

The merger was executed through a subsidiary of Angelini Pharma. Upon completion, the company’s certificate of incorporation and bylaws were restated in full. The directors of the company resigned, and new directors took their place, ensuring continuity of governance under the parent’s control and signal a clean transition of authority.

Market Reaction and Valuation Context

Catalyst’s shares have risen, reflecting a gain year-to-date and a modest rise over the past month. With a market capitalization, the stock sits near the top of its range. The cash payout closely mirrors the current trading price, effectively providing shareholders with a near-fair-value exit.

Investors who held the stock through the merger locked in gains that match the market’s recent premium.

Upcoming Milestones

The next critical date is when Nasdaq will suspend trading and the company will file a Form to formally deregister its securities. Following the deregistration, the company plans to submit a Form to terminate its reporting obligations under the Exchange Act. These filings will finalize the delisting process and end public reporting requirements, marking the final step of the transition.

Market participants should watch for the SEC’s acceptance of the filings, as any delay could affect the timing of the cash distribution finalization. Based on a recent filing.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.